A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid).
Akira SugimotoShingo MatsumotoHibiki UdagawaRyo ItotaniYuko UsuiShigeki UmemuraKazumi NishinoIchiro NakachiShoichi KuyamaHaruko DagaSatoshi HaraShingo MiyamotoTerufumi KatoJun Sakakibara KonishiEriko TabataTaku NakagawaTomoya KawaguchiTetsuya SakaiYuji ShibataHiroki IzumiKaname NosakiYoshitaka ZenkeKiyotaka YohKoichi GotoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Plasma cfDNA sequencing in advanced NSCLC patients showed relatively high sensitivity for detecting gene mutations but low sensitivity for gene fusions and MET exon 14 skipping. This may be an alternative only when tissue assay is unavailable due to insufficient DNA and RNA.
Keyphrases
- advanced non small cell lung cancer
- end stage renal disease
- epidermal growth factor receptor
- small cell lung cancer
- ejection fraction
- chronic kidney disease
- newly diagnosed
- single cell
- prognostic factors
- tyrosine kinase
- high throughput
- peritoneal dialysis
- genome wide
- patient reported outcomes
- copy number
- cell free
- ionic liquid
- dna methylation
- transcription factor
- simultaneous determination